Published in Eur J Cancer on August 10, 2006
Pharmacogenomics Study of CPT-11 as the First-line Chemotherapy for mCRC (PSIFL) | NCT01282658
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC | NCT03517618
Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst (2012) 2.52
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist (2012) 1.76
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer (2012) 1.31
Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol (2014) 1.26
TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. J Transl Med (2013) 1.07
Actual role of radiofrequency ablation of liver metastases. Eur Radiol (2007) 1.07
An update on chemotherapy of colorectal liver metastases. World J Gastroenterol (2012) 1.05
The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res (2012) 1.05
Treatment of colorectal liver metastases. World J Surg Oncol (2011) 1.04
Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nat Commun (2014) 1.04
A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis (2012) 1.02
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer (2011) 1.00
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer (2015) 0.99
Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis (2014) 0.95
Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg (2009) 0.93
Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. Br J Cancer (2013) 0.93
Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget (2015) 0.90
Laparoscopic hepatectomy for hepatic colorectal metastases -- a retrospective comparative cohort analysis and literature review. PLoS One (2013) 0.90
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer (2009) 0.90
Laparoscopic versus open hepatectomy with or without synchronous colectomy for colorectal liver metastasis: a meta-analysis. PLoS One (2014) 0.89
Liver resection for colorectal cancer metastases. Curr Oncol (2013) 0.89
Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. PLoS One (2014) 0.88
Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer (2013) 0.88
miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. PLoS One (2014) 0.87
Metastatic rectal cancer to the breast. Rare Tumors (2009) 0.87
Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol (2016) 0.85
HBV infection decreases risk of liver metastasis in patients with colorectal cancer: A cohort study. World J Gastroenterol (2011) 0.85
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer (2013) 0.85
Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol (2014) 0.84
CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer. Oncotarget (2016) 0.83
Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. World J Gastroenterol (2014) 0.83
Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur Radiol (2011) 0.82
Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study. Br J Cancer (2014) 0.81
Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma. Radiat Oncol (2013) 0.81
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer (2012) 0.81
Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer. J Cancer (2016) 0.81
Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging (2014) 0.80
Personalizing medicine for metastatic colorectal cancer: current developments. World J Gastroenterol (2014) 0.80
Cadherin-12 enhances proliferation in colorectal cancer cells and increases progression by promoting EMT. Tumour Biol (2016) 0.80
Timing of two-stage liver resection during chemotherapy for otherwise unresectable colorectal metastases. World J Surg (2012) 0.79
Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab. Jpn Clin Med (2014) 0.79
Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations. ISRN Minim Invasive Surg (2015) 0.79
Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. Oncol Lett (2012) 0.79
Anti-angiogenic agents in metastatic colorectal cancer. World J Gastrointest Oncol (2015) 0.79
Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. Onco Targets Ther (2016) 0.78
Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies. Oncol Rep (2016) 0.78
Role of surgery in colorectal liver metastases: too early or too late? World J Gastroenterol (2010) 0.78
Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Colorectal Dis (2011) 0.78
Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. World J Gastroenterol (2011) 0.78
Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer. JMIR Res Protoc (2017) 0.77
Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer. World J Gastroenterol (2010) 0.77
Therapeutic effect and tolerability of gelatin sponge particle-mediated chemoembolization for colorectal liver metastases: a retrospective study. World J Surg Oncol (2013) 0.77
Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective study. J Cancer Res Clin Oncol (2014) 0.77
Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases. World J Gastrointest Oncol (2016) 0.77
Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey. HPB (Oxford) (2014) 0.76
Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer. Curr Oncol (2014) 0.76
The preoperative SUVmax for (18)F-FDG uptake predicts survival in patients with colorectal cancer. BMC Cancer (2015) 0.76
Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. Curr Colorectal Cancer Rep (2015) 0.76
Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer (2016) 0.76
Current status of transarterial radioembolization. World J Radiol (2016) 0.76
Laparoscopic-assisted ablation of hepatic tumors: a review. Semin Intervent Radiol (2014) 0.76
A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases. Am J Cancer Res (2015) 0.76
Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther (2015) 0.76
Association of primary tumor lymph node ratio with burden of liver metastases and survival in stage IV colorectal cancer. Hepatobiliary Surg Nutr (2017) 0.75
Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore) (2016) 0.75
Deficiency in thrombopoietin induction after liver surgery is associated with postoperative liver dysfunction. PLoS One (2015) 0.75
Colorectal liver metastases; the current scenario. Indian J Surg Oncol (2011) 0.75
Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer. Exp Ther Med (2016) 0.75
TTF-1 Expression in Rectal Adenocarcinoma: A Case Report and Review of the Literature. Case Rep Oncol (2016) 0.75
Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series. HPB (Oxford) (2012) 0.75
The prognostic significance of the preoperative full blood count after resection of colorectal liver metastases. HPB Surg (2009) 0.75
Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford) (2013) 0.75
Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis. Medicine (Baltimore) (2016) 0.75
Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer. Medicine (Baltimore) (2016) 0.75
Effect of preoperative chemotherapy on postoperative liver regeneration following hepatic resection as estimated by liver volume. World J Surg Oncol (2013) 0.75
Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab. Indian J Surg Oncol (2015) 0.75
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. BMC Cancer (2014) 0.75
Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther Clin Risk Manag (2017) 0.75
Minimally Invasive Liver Surgery for Hepatic Colorectal Metastases. Curr Colorectal Cancer Rep (2016) 0.75
HINT2 downregulation promotes colorectal carcinoma migration and metastasis. Oncotarget (2017) 0.75
High-level expression of P21-Cdc/Rac-activated kinase 7 is closely related to metastatic potential and poor prognosis of colon carcinoma. Oncotarget (2016) 0.75
Multidisciplinary approach of colorectal cancer liver metastases. World J Clin Oncol (2017) 0.75
Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clin Exp Metastasis (2012) 0.75
Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer. Chin J Cancer (2014) 0.75
Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model. World J Gastroenterol (2015) 0.75
Avoiding hepatic metastasis naturally: Lessons from the cotton top tamarin (Saguinus oedipus). World J Gastroenterol (2016) 0.75
"Vanishing liver metastases"-A real challenge for liver surgeons. Hepatobiliary Surg Nutr (2014) 0.75
Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs. Gastroenterol Res Pract (2017) 0.75
The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Ther Adv Med Oncol (2010) 0.75
Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity. PLoS One (2017) 0.75
MicroRNA-34a suppresses colorectal cancer metastasis by regulating Notch signaling. Oncol Lett (2017) 0.75
Indeterminate Pulmonary Nodules in Resected Liver Metastases from Colorectal Cancer: A Comparison of Patient Outcomes. World J Surg (2017) 0.75
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
Colorectal cancer. Lancet (2010) 8.36
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 5.45
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol (2011) 4.77
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol (2006) 4.42
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol (2006) 3.46
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol (2009) 3.20
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg (2006) 3.05
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol (2012) 2.92
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer (2012) 2.79
Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol (2010) 2.66
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst (2012) 2.49
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst (2007) 2.42
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol (2005) 2.38
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol (2011) 2.26
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. J Biotechnol (2006) 2.12
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst (2007) 2.11
Colorectal metastasis (liver and lung). Surg Clin North Am (2002) 2.09
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol (2012) 2.07
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol (2011) 2.05
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]. Gastroenterol Clin Biol (2002) 2.04
7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. Ann Surg Oncol (2008) 2.00
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol (2008) 1.97
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood (2010) 1.96
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol (2009) 1.93
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev (2005) 1.85
Documented deaths of hepatic lobe donors for living donor liver transplantation. Liver Transpl (2006) 1.83
Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg (2010) 1.76
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist (2012) 1.76
Oncologic results of laparoscopic versus open hepatectomy for colorectal liver metastases in two specialized centers. Ann Surg (2009) 1.72
A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg (2012) 1.69
Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol (2012) 1.69
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol (2007) 1.63
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer (2007) 1.58
Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist (2005) 1.58
Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford) (2011) 1.56
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer (2004) 1.54
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol (2005) 1.52
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer (2011) 1.51
The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. Ann Surg (2007) 1.51
Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. Int J Colorectal Dis (2009) 1.50
Chemotherapy in elderly patients with colorectal cancer. Oncologist (2008) 1.48
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. Mol Cancer Ther (2013) 1.48
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
The role of new agents in the treatment of colorectal cancer. Oncology (2004) 1.45
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res (2007) 1.43
Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol (2012) 1.42
High fragmentation characterizes tumour-derived circulating DNA. PLoS One (2011) 1.42
Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol (2008) 1.39
Long-term remissions in metastatic malignant melanoma following chemotherapy and tamoxifen maintenance. Onkologie (2011) 1.39
The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer. Ann Surg (2008) 1.39
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol (2012) 1.36